Molekularbiologische Grundlagen der immunonkologischen Therapie

Ehrlich P. About the current state of carcinoma research. Ned. Tijdschr. Geneeskd. 1909;5: 273–90.

Wiemann B, Starnes CO. Coley‘s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64(3):529–64.

Galluzzi L et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1(5):699–716.

Rygaard J, Povlsen CO. Is immunological surveillance not a cell-mediated immune function? Transplantation. 1974;17(1):135–136.

Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27.

Dunn GP et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.

Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificityContinuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.

Schreiber RD et al. Cancer immunoediting: integrating immunity‘s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.

Anonymous. Genentech and IDEC await approval of lymphoma Mab. Nat Biotechnol. 1997;15(4):301.

Kobold S et al. Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol. 2010;71(7):643–51.

Kobold S et al. Immunotherapy in Tumors. Dtsch Arztebl Int. 2015;112(48):809–15.

Berman LD. Inhibition of oncogenicity of murine sarcoma virus (Harvey) in mice by interferon. Nature. 1970;227(5265):1349–50.

Ng RP et al. Transfer factor in Hodgkin‘s disease. Lancet. 1975;2(7941):901–3..

van Damme J et al. Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin 1 beta) from human leukocytes. Clin Exp Immunol. 1986;66(2):303–11.

Dinarello CA et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139(6):1902–10.

Lotze MT et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985;134(1):157–66.

Quesada JR et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310(1):15–8.

Eggermont AM et al. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4(7):429–37.

Atkins MB et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16.

Pfeffer LM et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58(12):2489–99.

Frei E 3rd, Spriggs D. Tumor necrosis factor: still a promising agent. J Clin Oncol. 1989;7(3):291–4.

Kobold S et al. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy. 2014;6(10):1085–95.

Badalament RA et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol. 1987;5(3):441–9.

Fountzilas C et al. Review: Oncolytic Virotherapy, updates and future directions. Oncotarget. Oncotarget. 2017 May 31. doi: 10.18632/oncotarget.18309. [Epub ahead of print].

Andtbacka RH et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780–8.

Zhukovsky EA et al. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016;40:24–35.

Heiss MM et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21.

Sebastian M et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother. 2007;56(10):1637–44.

Topp MS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.

Bargou R et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–7.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

Robert C et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med. 2015;372(4):320–30.

Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;22;373(17):1627–39.

Larkin J et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(13):1270–1.

Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–1833.

Robert C et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.

Brahmer JR et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

Kolb HJ et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462–5.

Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233–40.

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–8.

Maude SL et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.